Search company, investor...

NexGenix Pharmaceuticals Holdings

Founded Year


About NexGenix Pharmaceuticals Holdings

NexGenix Pharmaceuticals is developing drugs for cancer, neurodegenerative diseases, and neurofibromatosis.

Headquarters Location

152 West 57th Street Suite 11B

New York, New York, 10019,

United States

Missing: NexGenix Pharmaceuticals Holdings's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NexGenix Pharmaceuticals Holdings's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing NexGenix Pharmaceuticals Holdings

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NexGenix Pharmaceuticals Holdings is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

NexGenix Pharmaceuticals Holdings Patents

NexGenix Pharmaceuticals Holdings has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Rare diseases, Syndromes, Dermal and subcutaneous growths, Autosomal dominant disorders, Neurological disorders


Application Date


Grant Date



Related Topics

Rare diseases, Syndromes, Dermal and subcutaneous growths, Autosomal dominant disorders, Neurological disorders



NexGenix Pharmaceuticals Holdings Frequently Asked Questions (FAQ)

  • When was NexGenix Pharmaceuticals Holdings founded?

    NexGenix Pharmaceuticals Holdings was founded in 2003.

  • Where is NexGenix Pharmaceuticals Holdings's headquarters?

    NexGenix Pharmaceuticals Holdings's headquarters is located at 152 West 57th Street, New York.

  • Who are NexGenix Pharmaceuticals Holdings's competitors?

    Competitors of NexGenix Pharmaceuticals Holdings include Reata Pharmaceuticals, Bexion Pharmaceuticals, Rigel Pharmaceuticals, Acetylon Pharmaceuticals, Angstrom Pharmaceuticals and 16 more.

Compare NexGenix Pharmaceuticals Holdings to Competitors

Prolexys Pharmaceuticals

Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.

Nora Pharmaceuticals

Nora Pharmaceuticals, in stealth mode, is a developer of women's reproductive health drugs and devices.


MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

AiRNA Pharmaceuticals

AiRNA's focus is to develop RNAi drugs for cancer, inflammation, and infectious diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.